[ Clinical effect and side effect of troglitazone ] . DB00197 , a P37231 agonist , is a new drug for type 2 diabetes . The drug decreases blood glucose via enhancing insulin action . Recently Sankyo pharmaceutical company is warning severe hepatotoxicity by troglitazone . It recommends to examine liver function every month in diabetic patients treated with the drug in order early to find drug-induced hepatitis . In Japan 153 diabetic patients treated with the drug developed severe hepatitis and 8 of them died of drug-side effects . Quinone metabolite of troglitazone predominantly in the liver to a sulfate conjugate and activation of Q07869 gamma and O75469 ( pregnane X receptor ) by troglitazone are supposed to be factors of hepatotoxic mechanism .